%0 Journal Article
%A Sarink, Danja
%A Schock, Helena
%A Johnson, Theron Scot
%A Chang-Claude, Jenny
%A Overvad, Kim
%A Olsen, Anja
%A Tjønneland, Anne
%A Arveux, Patrick
%A Fournier, Agnès
%A Kvaskoff, Marina
%A Boeing, Heiner
%A Karakatsani, Anna
%A Trichopoulou, Antonia
%A La Vecchia, Carlo
%A Masala, Giovanna
%A Agnoli, Claudia
%A Panico, Salvatore
%A Tumino, Rosario
%A Sacerdote, Carlotta
%A van Gils, Carla H
%A Peeters, Petra H M
%A Weiderpass, Elisabete
%A Agudo, Antonio
%A Rodríguez-Barranco, Miguel
%A Huerta, José María
%A Ardanaz, Eva
%A Gil, Leire
%A Kaw, Kay Tee
%A Schmidt, Julie A
%A Dossus, Laure
%A His, Mathilde
%A Aune, Dagfinn
%A Riboli, Elio
%A Kaaks, Rudolf
%A Turzanski-Fortner, Renée
%T Receptor activator of nuclear factor kB ligand, osteoprotegerin, and risk of death following a breast cancer diagnosis: results from the EPIC cohort.
%J BMC cancer
%V 18
%N 1
%@ 1471-2407
%C Heidelberg
%I Springer
%M DKFZ-2018-01855
%P 1010
%D 2018
%X Receptor activator of nuclear factor kappa-B (RANK)-signaling is involved in tumor growth and spread in experimental models. Binding of RANK ligand (RANKL) to RANK activates signaling, which is inhibited by osteoprotegerin (OPG). We have previously shown that circulating soluble RANKL (sRANKL) and OPG are associated with breast cancer risk. Here we extend these findings to provide the first data on pre-diagnosis concentrations of sRANKL and OPG and risk of breast cancer-specific and overall mortality after a breast cancer diagnosis.Two thousand six pre- and postmenopausal women with incident invasive breast cancer (1620 (81
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:30348163
%2 pmc:PMC6196438
%R 10.1186/s12885-018-4887-3
%U https://inrepo02.dkfz.de/record/141336